Activin and Inhibin

BI-4916 is a proagent of BI-4924. BI-4924 is a NADH/NAD + -competitive PHGDH inhibitor.Form:Solid.

BI-4916 is a proagent of BI-4924. BI-4924 is a NADH/NAD + -competitive PHGDH inhibitor.

BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase ( PHGDH ) inhibitor ( IC 50 =3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine

BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase ( PHGDH ) inhibitor ( IC 50 =3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine

BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase ( PHGDH ) inhibitor ( IC 50 =3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine

BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase ( PHGDH ) inhibitor ( IC 50 =3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine

BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase ( PHGDH ) inhibitor ( IC 50 =3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine

BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF V600E -mutant, the WT

BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF V600E -mutant, the WT

BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF V600E -mutant, the WT

BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF V600E -mutant, the WT

BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays &gt:30-fold selectivity against NHE2 and with